Oral Epithelial Dysplasia
1
Pipeline Programs
2
Companies
2
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
2 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
2026
2027
2028
2029
2030
2031
Providence TherapeuticsCAN1012
Providence TherapeuticsCAN1012
Clinical Trials (2)
Total enrollment: 60 patients across 2 trials
CAN1012 in Pre-malignant Oral Dysplasia
Start: Jul 2026Est. completion: Jul 203336 patients
Phase 1Not Yet Recruiting
CAN1012 in Pre-Malignant DCIS and LCIS
Start: May 2026Est. completion: May 203524 patients
Phase 1Not Yet Recruiting
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
2 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.